You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR MILRINONE LACTATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for milrinone lactate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00446017 ↗ The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG Completed Deutsche Stiftung für Herzforschung Phase 3 2003-06-01 Myocardial dysfunction necessitating inotropic support is a typical complication after on-pump cardiac surgery. This prospective, randomized pilot-study analyses the metabolic and renal effects of the inotropes adrenaline and milrinone in patients needing inotropic support after coronary-artery-bypass-grafting. With respect to data derived from patients with sepsis shock and results from studies using phosphodiesterase-inhibitors prophylactically, the hypothesis is tested that adrenaline may be associated with unwarranted metabolic effects (hyperlactatemia and hyperglycemia) and renal dysfunction.
NCT00446017 ↗ The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG Completed University of Luebeck Phase 3 2003-06-01 Myocardial dysfunction necessitating inotropic support is a typical complication after on-pump cardiac surgery. This prospective, randomized pilot-study analyses the metabolic and renal effects of the inotropes adrenaline and milrinone in patients needing inotropic support after coronary-artery-bypass-grafting. With respect to data derived from patients with sepsis shock and results from studies using phosphodiesterase-inhibitors prophylactically, the hypothesis is tested that adrenaline may be associated with unwarranted metabolic effects (hyperlactatemia and hyperglycemia) and renal dysfunction.
NCT00695929 ↗ Levosimendan in Congenital Cardiac Surgery Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain N/A 2008-07-01 Many pediatric patients undergoing cardiac surgery under cardiopulmonary bypass for repair of complex congenital malformations, require inotropic support for low cardiac output syndrome. Milrinone through its positive inotropic and vasodilatory effects is widely used for this purpose. The aim of the study is to compare Milrinone with Levosimendan, a novel inotope with calcium-sensitizing properties. We hypothesized that using Levosimendan would result in reduced serum lactate through a higher cardiac index.
NCT01088997 ↗ Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn Terminated American Medical Association N/A 2010-06-01 The purpose of this pilot study is to determine a safe dose of milrinone to use in a larger study of babies with persistent pulmonary hypertension of the newborn (PPHN).
NCT01088997 ↗ Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn Terminated Bedford Pharmaceuticals N/A 2010-06-01 The purpose of this pilot study is to determine a safe dose of milrinone to use in a larger study of babies with persistent pulmonary hypertension of the newborn (PPHN).
NCT01088997 ↗ Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn Terminated Thrasher Research Fund N/A 2010-06-01 The purpose of this pilot study is to determine a safe dose of milrinone to use in a larger study of babies with persistent pulmonary hypertension of the newborn (PPHN).
NCT01088997 ↗ Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn Terminated University of Pennsylvania N/A 2010-06-01 The purpose of this pilot study is to determine a safe dose of milrinone to use in a larger study of babies with persistent pulmonary hypertension of the newborn (PPHN).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for milrinone lactate

Condition Name

Condition Name for milrinone lactate
Intervention Trials
Low Cardiac Output Syndrome 3
Cardiac Output, Low 1
Cardiac Surgical Procedures 1
Cardiogenic Shock 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for milrinone lactate
Intervention Trials
Cardiac Output, Low 4
Syndrome 2
Critical Illness 1
Acute Coronary Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for milrinone lactate

Trials by Country

Trials by Country for milrinone lactate
Location Trials
United States 2
Canada 1
Belgium 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for milrinone lactate
Location Trials
Pennsylvania 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for milrinone lactate

Clinical Trial Phase

Clinical Trial Phase for milrinone lactate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for milrinone lactate
Clinical Trial Phase Trials
Completed 3
Terminated 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for milrinone lactate

Sponsor Name

Sponsor Name for milrinone lactate
Sponsor Trials
University of Luebeck 1
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 1
American Medical Association 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for milrinone lactate
Sponsor Trials
Other 9
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.